Klamkin Jonathan sold $1.1M of ALMU (indirect holdings)
Klamkin Jonathan (Chief Executive Officer) sold 100,000 indirectly-held shares of Aeluma, Inc. (ALMU) at $10.53 ($1.05M total) on 2026-10-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the CEO's ownership and may be interpreted as a bearish signal, though the pre‑arranged plan tempers speculation.
Market read
A modest insider sell that could slightly depress the stock, but unlikely to move the broader market.
What to watch
Potential upcoming corporate actions or financing needs that prompted the sale.
Background
SEC Form 4 filings disclose insider transactions and are primary sources for insider activity.
Ticker impact
CEO Jonathan Klamkin sold 100,000 shares for $1.05M via a 10b5‑1 plan, reducing his stake to 1,126,995 shares.
likely downward pressure as the market prices the insider sell
A chief executive selling over $1M of stock, even via a pre‑arranged plan, is often viewed as a negative signal by investors.
Market effects
Minimal impact on the broader sector; the sale is company‑specific.
No regional effect; limited to ALMU shareholders.
Negligible; the filing does not affect global markets.
Counterpoint
The sale may be purely procedural under the 10b5‑1 plan and not reflect any lack of confidence.
Key entities
- personJonathan Klamkin
Chief Executive Officer of Aeluma, Inc.
- companyAeluma, Inc.
Biopharma company listed under ticker ALMU.
